Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK2 | Q9HBH9 | 16/20 | 0.63 |
| ▸ | MKNK1 | Q9BUB5 | 9/20 | 0.63 |
| ▸ | EIF4E | P06730 | 2/20 | 0.63 |
| ▸ | AURKA | O14965 | 1/20 | 0.43 |
| ▸ | TEK | Q02763 | 1/20 | 0.43 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.41 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.41 |
| ▸ | FADS1 | O60427 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13434850 | 0.87 | MKNK2 (0.59) | MKNK2MKNK1EIF4EEGFR | |
| SCHEMBL13434851 | 0.84 | DYRK1A (0.55) | MKNK2MKNK1EIF4EAURKATEK | |
| SCHEMBL3803642 | 0.83 | MKNK1 (0.57) | MKNK2MKNK1EIF4EEGFR | |
| SCHEMBL13434842 | 0.83 | MKNK2 (0.44) | MKNK2MKNK1EIF4EAURKAAURKB | |
| SCHEMBL13434854 | 0.80 | EGFR (0.47) | MKNK2MKNK1EIF4EAURKATEK | |
| SCHEMBL13434849 | 0.79 | MKNK2 (0.53) | MKNK2MKNK1EIF4EAURKATEK | |
| SCHEMBL18839802 | 0.77 | MKNK2 (0.61) | MKNK2MKNK1EIF4E | |
| SCHEMBL20575252 | 0.77 | MKNK2 (1.00) | MKNK2MKNK1EIF4E | |
| SCHEMBL13434847 | 0.77 | MKNK2 (0.54) | MKNK2MKNK1EIF4EAURKATEK | |
| SCHEMBL23049793 | 0.76 | MKNK2 (0.98) | MKNK2MKNK1EIF4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8633201-B2 | Thienopyrimidines having Mnk1/Mnk2 inhibiting activity for pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-21 | — | — | US | disclosed |